Literature DB >> 2256173

The prevalence of hyperlipidemia in renal transplant recipients. Associations with immunosuppressive and antihypertensive therapy.

A E Bittar1, P J Ratcliffe, A J Richardson, A E Raine, L Jones, P L Yudkin, R Carter, J I Mann, P J Morris.   

Abstract

To determine the extent of persisting hyperlipidemia in renal transplant recipients receiving modern maintenance immunosuppressive and antihypertensive therapy we compared plasma levels of total and high-density lipoprotein and triglyceride in 275 renal transplant recipients with stable graft function with age- and sex-matched groups from the local general population (n = 4055). Total cholesterol and triglyceride were higher in transplanted patients in all age groups, but the difference was much more striking in women. Plasma levels of HDL cholesterol were similar or slightly lower in transplanted patients. Association with parameters of graft function, immunosuppressive therapy, and antihypertensive therapy were studied within the transplanted population using multiple regression. Total cholesterol was significantly and independently associated with age, sex, diuretic therapy, and urinary protein. In 127/134 (95%) of patients the diuretic was a loop diuretic. None of the other classes of antihypertensive drug was independently associated with serum cholesterol. The only variables significantly associated with HDL cholesterol were sex and the plasma creatinine. Plasma triglyceride was significantly and independently associated with both diuretic therapy and beta-blocker therapy and with age, urinary protein excretion, and plasma albumin. Plasma cholesterol, HDL cholesterol, and triglyceride levels were almost identical in patients receiving triple therapy (cyclosporine 3-5 mg/kg; prednisolone 7-10 mg o.d.; azathioprine 1-1.5 mg/kg) to those in patients receiving conventional immunosuppression (prednisolone 7-10 mg o.d.; azathioprine 2-2.5 mg/kg). Thus these results do not support the existence of a persisting long-term effect of cyclosporine on plasma cholesterol and triglyceride at these doses of the drug. The more striking abnormality of plasma cholesterol and triglyceride in females is unexplained but might be connected with greater sensitivity to low doses of corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2256173     DOI: 10.1097/00007890-199012000-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  Primary care of the renal transplant patient.

Authors:  J D Pirsch; R Friedman
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

Review 2.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

3.  Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant.

Authors:  Vijay Shivaswamy; R Brian Stevens; Ramona Zephier; Myhra Zephier; Junfeng Sun; Gerald Groggel; Judi Erickson; Jennifer Larsen
Journal:  Transplantation       Date:  2008-05-15       Impact factor: 4.939

4.  [Metabolic complications after renal transplantation from a living donor: experience of the Ibn Sina university hospital of Rabat].

Authors:  Hala Mouram; Loubna Benamar; Naima Ouzeddoune; Rabia Bayahia; Fatima Ezaitouni
Journal:  Pan Afr Med J       Date:  2014-06-19

5.  Should post kidney transplantation hyperlipidemia considered a risk factor for graft function?

Authors:  G Pourmand; A Saraji; S Dehgani; A Mehrsai; M Nikoobakht; M Talibnajad; E Razeghi; M Rahbar; H Hosseini; N Pourmand; Sh Pourmand; M Zahedikia; M Porhussein; F Heidari
Journal:  Int J Organ Transplant Med       Date:  2010

6.  Effects of lipid metabolism on mouse incisor dentinogenesis.

Authors:  Yutaro Kurotaki; Nobuhiro Sakai; Takuro Miyazaki; Masahiro Hosonuma; Yurie Sato; Akiko Karakawa; Masahiro Chatani; Mie Myers; Tetsuo Suzawa; Takako Negishi-Koga; Ryutaro Kamijo; Akira Miyazaki; Yasubumi Maruoka; Masamichi Takami
Journal:  Sci Rep       Date:  2020-03-20       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.